अमूर्त

Immune Rousing and Inflammatory Modulation as Key Bottlenecks for Improving Cancer Outcome; The use of Bioactive Compounds from Rosmarinus Officinalis as Therapy

Juan Jose Montoya, Youness Ouahid, Carbache MF, Eugenio Rodriguez Nunez, Empar Sainz, Antoni Molera, Torres CF, Reglero G, Joaquin Carballido Rodríguez, Castan Pablo

Animal studies provide evidences of changes in tumour growth and cancer progression when subjects are fed with diets including certain bioactive elements. Unluckily, the molecular mechanisms through which most diet-derived ingredients contribute to improve cancer response are still to be characterized. In this context, the application of certain “omics” techniques such as, transcriptomics, proteomics, metabolomics and metagenomics have pointed at general mechanisms positively affected by precision nutrition in terms of modulating the immune system's responses to harmful stimuli, such as damaged cells, toxic compounds or uncontrolled cell growth. Those mechanisms normally correlate with a) the modulation of the inflammation needed to remove injurious stimuli triggering the healing process and b) the stimulation of the immune pliability needed to expand antitumor responses. Interestingly enough, increased immune capabilities and reduced inflammatory responses have also been historically observed in individuals with healthy life-styles and nutritional habits.

This work reports the use of one advanced machine learning model used to analyse modelled transcriptomes and proteomes from 7.500 oncologic patients in 3 major cohorts including Lung Cancer (LC), Colorectal Cancer (CRC) and Breast Cancer (BC). The analysis aimed to gain molecular knowledge on the two aforementioned mechanisms through which bioactive compounds induce the activation of the immune system and reduce the inflammatory response associated to cancer related harmful stimuli. Cross-sectional analysis and scrutiny between a) the Molecular Trigger Points (MTPs) elucidated by the A.I. and b) the reported mechanism of action for extracts from Rosmarinus officinalis L. (syn Salvia Rosmarinus Spenn.) suggest fitness for use of a bioactive formula based on diterpenic phenols from rosemary, formulated with bioactive alkylglycerols (OncoLipchronic® WO/2017/187000) in cancer patients. Furthermore, the high correlation between the MTPs and the effects registered for the bioactive formula open the space for further clinical confirmation of the immune activation and inflammatory modulation in cancer patients in order to define if a better clinical outcome can be obtained associating the purely medical treatment to the supplementation with OncoLipchronic® (Lipchronic).